Literature DB >> 21745311

Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels.

Jae Y Cheong1, Dong J Kim, Seong G Hwang, Jin M Yang, Young B Kim, Young N Park, Sung W Cho.   

Abstract

BACKGROUND: Reports on the usefulness of serum markers for predicting liver necroinflammation are limited. The aim of this study was to determine the serum markers that predict significant inflammation in patients with chronic hepatitis B (CHB) and C (CHC) and normal or mildly elevated serum aminotransferase levels.
METHODS: Two hundred twenty-seven patients with CHB or CHC with normal or mildly elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (≤60 IU/L) were enrolled in this study. Significant inflammation was defined as inflammatory grade ≥3 activities using the Batt-Ludwig scoring system. The correlation between liver histology and serum markers of liver inflammation was analysed.
RESULTS: Forty-eight (21.1%) and eight patients (3.5%) had grade 3 and 4 inflammation respectively. Univariate analysis revealed that age, platelet coun, and AST, ALT, γ-glutamyl transpeptidase, alkaline phosphatase, hyaluronic acid, haptoglobin, apolipoprotein A1 and procollagen III N-terminal peptide levels were significantly different between the patients with and without significant inflammation. There were no significant differences in the cytokeratin-18 fragment levels between the two groups. On the basis of multivariate analysis, the AST and apolipoprotein A1 levels and stage of fibrosis were highly predictive of significant inflammation. Using AST and apolipoprotein cut-off values ≥44 IU/L and ≤100 ng/ml, respectively, the presence of significant inflammation was predicted with high specificity (96.5%) and with a negative predictive value of 76.3%.
CONCLUSION: The AST and apolipoprotein A1 levels were shown to be independent predictors of significant inflammatory activities in patients with CHB and CHC and normal or mildly elevated aminotransferase levels.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745311     DOI: 10.1111/j.1478-3231.2011.02570.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  14 in total

1.  Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.

Authors:  Rui Liao; De-Wei Li; Cheng-You Du; Ming Li
Journal:  J Gastrointest Surg       Date:  2018-05-18       Impact factor: 3.452

2.  Liver stiffness measurement-based scoring system for significant inflammation related to chronic hepatitis B.

Authors:  Mei-Zhu Hong; Ru-Mian Zhang; Guo-Liang Chen; Wen-Qi Huang; Feng Min; Tian Chen; Jin-Chao Xu; Jin-Shui Pan
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

3.  The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus.

Authors:  Yuanyuan Wang; Junli Hao; Xiaohong Liu; Hongxin Wang; Xin Zeng; Jing Yang; Lei Li; Xi Kuang; Tao Zhang
Journal:  Lipids Health Dis       Date:  2016-03-25       Impact factor: 3.876

4.  Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients.

Authors:  Jin-Lin Cheng; Xiao-Ling Wang; Shi-Gui Yang; Hong Zhao; Jing-Jing Wu; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

5.  Noninvasive scoring system for significant inflammation related to chronic hepatitis B.

Authors:  Mei-Zhu Hong; Linglong Ye; Li-Xin Jin; Yan-Dan Ren; Xiao-Fang Yu; Xiao-Bin Liu; Ru-Mian Zhang; Kuangnan Fang; Jin-Shui Pan
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

6.  Serum GP73 - An Additional Biochemical Marker for Liver Inflammation in Chronic HBV Infected Patients with Normal or Slightly Raised ALT.

Authors:  Meijuan Wei; Zhengju Xu; Xingnan Pan; Xiaoman Zhang; LiGuan Liu; Bishuang Yang; Yuxia Chen
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

7.  Clinical Non-invasive Model to Predict Liver Inflammation in Chronic Hepatitis B With Alanine Aminotransferase ≤ 2 Upper Limit of Normal.

Authors:  Shanshan Chen; Haijun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-02

8.  The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis.

Authors:  Sua Sumer; Nazlim Aktug Demir; Servet Kölgelier; Ahmet Cagkan Inkaya; Abdullah Arpaci; Lütfi Saltuk Demir; Onur Ural
Journal:  Hepat Mon       Date:  2013-06-26       Impact factor: 0.660

9.  Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma: development and validation of a predictive model.

Authors:  Kyu Sik Jung; Ji Hong Kim; Seung Up Kim; Kijun Song; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Do Chang Moon; In Ji Song; Gi Hong Choi; Young Nyun Park; Kwang-Hyub Han
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

Review 10.  New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article.

Authors:  Hedyeh Ebrahimi; Mohammadreza Naderian; Amir Ali Sohrabpour
Journal:  Middle East J Dig Dis       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.